SCHEMBL1285133

SCHEMBL1285133

NC(=O)CC(n1ccc2cnc(Nc3ccc(-n4cncn4)cc3)nc21)C1(C(=O)O)CCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 4/20 0.46
▸ TBK1 Q9UHD2 1/20 0.40
▸ MAPK10 P53779 1/20 0.39
▸ STAT6 P42226 4/20 0.39
▸ JAK3 P52333 6/20 0.35
▸ JAK2 O60674 3/20 0.34
▸ JAK1 P23458 2/20 0.34
▸ TYK2 P29597 1/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ CCNT1 O60563 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ CDK4 P11802 1/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ CCNE1 P24864 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ CCND3 P30281 1/20 0.33
▸ CDK7 P50613 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27844373 0.91 SYK (0.45) SYKTBK1MAPK10STAT6JAK3
SCHEMBL1284716 0.91 AURKA (0.38) SYKSTAT6JAK3JAK2TYK2
SCHEMBL1284543 0.84 STAT6 (0.51) SYKMAPK10STAT6JAK2BRD4
SCHEMBL1284285 0.83 CDK4 (0.51) STAT6JAK3JAK2PDGFRABRD4
SCHEMBL1284917 0.82 MAPK8 (0.47) SYKMAPK10STAT6JAK3CCNT1
SCHEMBL1284926 0.82 CDK4 (0.40) CDK4CCNA2CCND1CDK2CCND3
SCHEMBL28793685 0.82 AURKA (0.39) SYKTBK1JAK3JAK2TYK2
SCHEMBL1284416 0.82 JAK3 (0.49) SYKJAK3JAK2JAK1TYK2
SCHEMBL1284506 0.81 CAMK2D (0.43) TBK1STAT6JAK3JAK2JAK1
SCHEMBL1284584 0.81 SYK (0.45) SYKTBK1STAT6JAK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088753-A1 PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2012-04-12 — — US claimed
EP-2403853-A1 PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS Medical Research Council Technology (GB) 2012-01-11 — — EP claimed
US-20120088753-A1 PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2012-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088753-A1 PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS MARK3, MAPK8, CDK8 SYK 230/4885TBK1 17/4885MAPK10 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback